AxoGen Inc

AXGN

31.280USD

-0.970-3.01%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

AxoGen Inc's Score

Industry at a Glance

Industry Ranking

10 / 208

Overall Ranking

77 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

AxoGen Inc Highlights

StrengthsRisks

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 41.63% year-on-year.

Undervalued

The company’s latest PE is -91.73, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 42.08M shares, increasing 0.02% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.15K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.01.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

40.800

Target Price

+26.51%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of AxoGen Inc is 6.92, ranking 100 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 59.90M, representing a year-over-year increase of 21.25%, while its net profit experienced a year-over-year increase of 3023.56%.

Score

Industry at a Glance

Previous score

6.92

Change

0



Financials

8.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.17

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.11

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.06

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.13

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of AxoGen Inc is 7.42, ranking 88 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -91.73, which is -92.76% below the recent high of -6.64 and -822.28% above the recent low of -846.01.

Score

Industry at a Glance

Previous score

7.42

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 10/208

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of AxoGen Inc is 8.40, ranking 34 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 36.00, with a high of 40.00 and a low of 27.00.

Score

Industry at a Glance

Previous score

8.40

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of AxoGen Inc is 9.01, ranking 7 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 34.49 and the support level at 27.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.31

Change

-0.3

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of AxoGen Inc is 10.00, ranking 1 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 97.83%, representing a quarter-over-quarter decrease of 3.81%. The largest institutional shareholder is The Vanguard, holding a total of 2.86M shares, representing 5.51% of shares outstanding, with 0.84% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

First Light Asset Management, LLC

5.81M

+28.18%

BlackRock Institutional Trust Company, N.A.

3.18M

+2.47%

The Vanguard Group, Inc.

Star Investors

2.67M

-1.87%

Morgan Stanley & Co. LLC

2.29M

+18.22%

ArrowMark Colorado Holdings, LLC

1.96M

+20.45%

Assenagon Asset Management S.A.

1.29M

+25.99%

Soleus Capital Management, L.P.

1.73M

+18.31%

Geode Capital Management, L.L.C.

1.08M

+1.78%

State Street Investment Management (US)

1.11M

-1.10%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of AxoGen Inc is 5.93, ranking 70 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.00. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

AxoGen Inc

AXGN

7.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

8.39 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Bioventus Inc

BVS

8.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Anika Therapeutics Inc

ANIK

8.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Edwards Lifesciences Corp

EW

8.05 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment